Denali Therapeutics Inc. (DNLI) Operating income 2016–2025
Denali Therapeutics Inc. (DNLI) annual operating income history from SEC filings — each fiscal year as reported.
-$555.3MFY2025 · since FY2016: -$87.4M → -$555.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$555.3M | -14.0% |
| FY2024 | -$487.3M | -147.8% |
| FY2023 | -$196.7M | +42.3% |
| FY2022 | -$340.7M | -15.2% |
| FY2021 | -$295.8M | -571.6% |
| FY2020 | $62.7M | +129.4% |
| FY2019 | -$213.2M | -359.7% |
| FY2018 | -$46.4M | +48.6% |
| FY2017 | -$90.1M | -3.1% |
| FY2016 | -$87.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DNLI financial trends
DNLI RevenueDNLI Net incomeDNLI Net marginDNLI Gross profitDNLI Gross marginDNLI Operating marginDNLI Operating cash flowDNLI Free cash flowDNLI Capital expendituresDNLI Return on equityDNLI Stock buybacksDNLI Dividends paidDNLI Total assetsDNLI Total liabilitiesDNLI Shareholders’ equityDNLI overview →